We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TAVNEOS (Vifor Pharma Pty Ltd)
Product name
TAVNEOS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
202 (255 working days)
Active ingredients
avacopan
Registration type
NCE/NBE
Indication
Tavneos, in combination with a rituximab or cyclophosphamide based regimen, is indicated for the treatment of adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.